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Abstract  
Cerebral amyloid angiopathy (CAA) and β-amyloid (Aβ) deposition in the brain parenchyma 
are hallmarks of Alzheimer’s disease (AD). We previously reported that platelets contribute to 
Aβ aggregation in cerebral vessels by secreting clusterin in response to the binding of Aβ40 to 
the fibrinogen receptor integrin αIIbβ3 [also known as glycoprotein IIb/IIIa (GPIIb/IIIa)]. Here, 
we investigated the contribution of glycoprotein VI (GPVI), a cardiovascular disease-associated 
collagen receptor, in platelet-induced amyloid aggregation. Using platelets isolated from GPVI-
wildtype and GPVI-deficient human donors and mice, we found that Aβ40 bound to GPVI and 
induced tyrosine phosphorylation on target proteins that mediated the release of ATP and 
fibrinogen, resulting in platelet aggregation. Binding of Aβ40 to integrin αIIbβ3 (as previously 
reported), fibrinogen and GPVI led to the formation of amyloid clusters at the platelet surface. 
Consequently, pharmacological blockade of integrin αIIbβ3 or genetic loss of GPVI reduced the 
phosphorylation of LAT and amyloid fibril formation in cultured platelets and decreased the 
adhesion of Aβ-activated platelets to the injured carotid artery in mice. Blocking GPVI-
mediated signaling non-selectively with losartan decreased platelet activation, ATP and 
fibrinogen release, and Aβ40-stimulated platelet aggregation, although it did not reduce the 
formation of amyloid aggregates. Our findings indicate that Aβ40 binds to GPVI as well as 
integrin αIIbβ3 to promote platelet-mediated amyloid aggregation and, hence, blocking these 
pathways may therapeutically reduce amyloid plaque formation in cerebral vessels and the brain 















In 2015, there were more than 47 million people living with dementia worldwide. With 
increasing age and the lack of effective therapeutic strategies, this number is projected to rapidly 
increase, reaching 135 million people by 2050 (1, 2). Alzheimer's disease (AD) is the most 
frequent cause of dementia, accounting for 60 % of dementia cases (3). The pathological 
hallmarks of AD are elevated misfolding, oligomerization and aggregation of β-amyloid (Aβ) 
peptides in brain parenchyma and in the cerebral vessels, known as cerebral amyloid angiopathy 
(CAA), and accumulation of intracellular neurofibrillary tangles (NFTs) in neurons (4, 5). The 
consequences are neurodegeneration with synaptic and neuronal loss leading to brain atrophy 
(6, 7). 
Several studies indicate that vascular damage and dysfunction, including reduction of cerebral 
blood flow (CBF), cerebral amyloid angiopathy and blood-brain barrier (BBB) disturbances, 
contribute to the onset and progression of AD (8). Vascular risk factors such as atherosclerosis, 
stroke, hypertension and diabetes lead to vascular damage and are associated with AD. 
However, whether the processes in the vasculature initiate the pathologic process of Aβ 
aggregation is still uncertain. Identifying the mechanisms underlying vascular pathophysiology 
that contribute to neurodegeneration in AD will help identify novel therapeutic targets. 
Besides the role of platelets in thrombus formation during hemostasis, it is becoming clear that 
platelets play a crucial role in a number of other processes within the vasculature such as 
angiogenesis, inflammation and cancer (9-11). Moreover, alterations in platelet function are 
also observed in diverse neurological diseases such as Parkinson disease, schizophrenia, autism 
and AD (12-15). A higher baseline expression of platelet activation biomarkers was measured 
in AD patients (16) and the analysis of the Alzheimer mouse model APP23 showed these mice 
have a pro-thrombotic phenotype (17, 18). Moreover, APP23 mice develop CAA and exhibit 
platelet accumulation at vascular plaques leading to the reduction of cerebral blood flow and 
probably to occlusion of cerebral vessels (18). The ability of platelets to modulate soluble, 
synthetic Aβ40 into fibrillar Aβ in vitro indicates a direct impact of platelets in the aggregation 
property of Aβ40 peptides (18-20). Previously we have demonstrated platelets contribute to 
amyloid-β aggregation through binding of Aβ40 to the fibrinogen receptor integrin αIIbβ3 
leading to outside-in signaling in platelets (19, 20) and inhibition of integrin αIIbβ3 on the surface 
of platelets prevents the aggregation of Aβ40 in cultured cells (19). An important indication of 
the involvement of platelets in Aβ aggregation in vivo was shown by the treatment of APP23 
mice with the antiplatelet agent clopidogrel, a P2Y12 antagonist. Clopidogrel reduced the 
incidence of CAA with less adherent platelets at vascular Aβ deposits in transgenic AD mice 
(19). Here, we investigated the involvement of other receptors on the surface of platelets and 
uncovered a critical role for the collagen receptor glycoprotein VI (GPVI) in platelet-mediated 





Phosphorylation of tyrosine residues in LAT and other proteins by GPVI and integrin 
αIIbβ3 in response to Aβ40 stimulation 
Binding of collagen to GPVI leads to a series of downstream signals in platelets, resulting in 
phosphorylation and activation of various signaling proteins, including the adaptor protein LAT 
(linker of activated T cells) (21). The stimulation of human platelets with soluble Aβ40 induced 
a similar pattern of tyrosine phosphorylation compared to the stimulation of platelets with CRP 
as shown by Western blot analysis (Fig. 1A).  Aβ40 also induced the phosphorylation of LAT 
(Fig. 1B) and in a time-dependent manner, with a maximum abundance detected at 90 s of 
incubation (fig. S1). Previously, we demonstrated that binding of Aβ40 to integrin αIIbβ3 induces 
integrin outside-in signaling. To exclude this effect, we performed studies in the presence of 
human blocking integrin αIIbβ3 antibody Abciximab. Blocking of integrin αIIbβ3 decreased the 
phosphorylation of tyrosine (Fig. 1A) and LAT (Fig. 1B) induced by Aβ40. In addition, we 
used platelets from patients who lack the GPVI receptor. Human GPVI-deficient platelets did 
not show phosphorylation of LAT neither after stimulation with collagen nor by Aβ40 
stimulation (Fig. 1C). However, Aβ40 induced phosphorylation of LAT was higher than upon 
activation with low concentration of collagen. Moreover, we studied the effect of Aβ40 in 
mouse platelets deficient in GPVI. Compared to wild type platelets, GPVI-deficient platelets 
failed to induce phosphorylation of LAT both upon CRP and Aβ40 activation (Fig. 1D). These 




Reduced ATP release of GPVI-deficient platelets in response to Aβ40 
Activation of GPVI through collagen induces platelet activation leading to secretion of 
granules, inside-out signaling of integrin αIIbβ3 and platelet aggregation (22). To study the 
consequence of GPVI activation through Aβ40, we measured the release of ATP upon 
Aβ40 stimulation in human platelets. Previous studies showed that losartan inhibits collagen 
induced platelet aggregation through GPVI (23, 24). Therefore, we analyzed the effects of 
losartan treatment on Aβ40 induced platelet stimulation. Aβ40 induced the release of ATP, 
however the amount of ATP was lower compared to CRP stimulation of platelets (Fig. 2A and 
B). To test whether Aβ40 induced ATP release is altered by losartan, platelets were pre-
incubated with losartan. The release of ATP was reduced by losartan following stimulation of 
platelets with either CRP or Aβ40 (Fig. 2, A and B). WT and GPVI-knockout mice were 
analyzed to confirm that Aβ40 induces a release of ATP release via GPVI. The release of ATP 
in response to CRP or Aβ40 was significantly reduced using GPVI deficient platelets compared 
to wild type controls. Blocking of integrin αIIbβ3 using Leo.H4 antibody in WT platelets resulted 
in significantly reduced ATP release as well (Fig. 2C). Thus, Aβ40 induced release of ATP is 
mediated by GPVI and integrin αIIbβ3. Therefore, blocking of integrin αIIbβ3 in WT platelets 
reduced ATP release to resting levels (Fig. 2C). 
 
Strongly reduced aggregation of GPVI deficient platelets in response to Aβ40 
Next we analyzed platelet aggregation after Aβ40 stimulation.  Aβ40 induced platelet 
aggregation that was comparable to that induced by CRP (Fig. 3A). Additionally, we analyzed 
the effect of losartan on Aβ40-induced platelet aggregation (Fig. 3A and B). In agreement with 
reported data, losartan significantly inhibited CRP- and Aβ40-induced platelet aggregation 
(Fig. 3A and B). To confirm the role of GPVI in Aβ40induced platelet aggregation, we used 
platelets from patients with GPVI deficiency. As expected, these platelets showed no platelet 
aggregation in response to Aβ40 compared to platelets from healthy controls (Fig. 3C and D). 
Moreover, we analyzed platelets from WT and GPVI-deficient mice. The aggregation response 
of WT mouse platelets with Aβ40 was comparable to CRP-induced platelet aggregation (Fig. 
3E and F). As expected, GPVI-deficient mouse platelets showed no aggregation upon CRP 
stimulation. Platelet aggregation upon Aβ40 stimulation was reduced in GPVI-deficient 
platelets compared to WT platelets (Fig. 3F). In contrast to CRP stimulation, we still measured 
a slight platelet aggregation of GPVI-deficient platelets in response to Aβ40, suggesting that 
Aβ40 can induce platelet aggregation without GPVI. These results demonstrated that activation 
of GPVI by Aβ40 binding induced platelet aggregation.  
 
Decreased amyloid aggregate formation by GPVI inhibition or genetic deletion in vitro 
In our previous study, we showed that platelets are able to modulate soluble Aβ40 to fibrillar 
Aβ aggregates while blocking of integrin αIIbβ3 on the surface of platelets prevents Aβ aggregate 
formation (19). To investigate a role of GPVI in platelet mediated Aβ aggregate formation, 
human platelets were pretreated with losartan and incubated with soluble, synthetic Aβ40 for 3 
days. The formation of fibrillar Aβ aggregates were analyzed by congo red staining. Although 
Aβ40 induced platelet aggregation and ATP release were reduced in the presence of losartan, 
we did not observe alterations in Aβ aggregation in platelet cell culture (Fig. 4A).  Neither daily 
addition nor different concentrations of losartan were able to reduce fibrillar Aβ aggregate 
formation (fig. S2A to C). 
Because losartan is not a specific GPVI inhibitor, mouse platelet experiments were performed 
where GPVI was blocked by antibody treatment with JAQ1. In addition, the antibody Leo.H4 
was used to block integrin αIIbβ3 to confirm the essential role of integrin αIIbβ3 in Aβ aggregate 
formation. The formation of Aβ aggregates was completely inhibited by blocking of integrin 
αIIbβ3 and strongly reduced by blocking of GPVI (Fig. 4B). The inhibitory effect of GPVI 
blockage in platelet cell culture was dose-dependent (fig. S3A). The quantification of remaining 
soluble Aβ40 in the supernatants of platelet cell culture by Western blot analysis showed 
significantly increased amounts of Aβ40 when GPVI was blocked compared to untreated 
platelets consistent with reduced Aβ aggregate formation (Fig. 4C and D). To confirm these 
results, we used platelets from GPVI-deficient mice for cell culture experiments. Cultures of 
platelets from GPVI knockout mice displayed markedly reduced Aβ aggregate formation (Fig. 
4E). In the supernatants of GPVI-deficient platelets we measured significantly increased 
amounts of soluble Aβ40 compared to WT platelets (Fig. 4F and G). The additional blocking 
of integrin αIIbβ3 by antibody Leo.H4 led to increasing amounts of soluble Aβ40 in the 
supernatant compared to GPVI deficiency alone and to complete inhibition of Aβ aggregates in 
cell culture (Fig. 4E to G). 
 
Direct binding of Aβ40 to GPVI  
To elucidate the mechanisms by which Aβ40 peptides induce GPVI activation, we investigated 
the interaction between GPVI and Aβ40. First, we used the microarray AVEXIS screening 
assay (25). No binding with a control protein (CD200R-BLH) but direct binding of pentameric 
GPVI to Aβ40 peptides was observed (Fig. 5A and B). In a second approach, we confirmed the 
interaction of both proteins by the use of immobilized magnetic beads coated with recombinant 
GPVI and incubated with soluble Aβ40. After pulldown, the association was visualized by 
Western blotting using antibodies to GPVI and Aβ (Fig. 4C). When Aβ40 was passed through 
GPVI-bound beads, a large amount of Aβ was detected along with GPVI. To verify the 
interaction between GPVI on platelets and Aβ40 in vitro, we incubated murine platelets with 
Aβ40 peptides and immunoprecipitated GPVI with the antibody JAQ1. Western blot analysis 
demonstrated that Aβ peptides were co-immunoprecipitated with GPVI (Fig. 4D). To show the 
relevance of GPVI for Aβ binding to platelets, platelets from GPVI-deficient and WT mice 
were incubated with Aβ40 peptides. Using flow cytometry, binding of Aβ40 to platelets was 
detected by FITC labeled Aβ antibody (Fig. 4E). Binding of Aβ to GPVI deficient platelets was 
significantly reduced compared to WT platelets. Additionally, binding of Aβ to platelets was 
increased upon stimulation with both CRP and soluble Aβ40 and significantly reduced by 
integrin αIIbβ3 blocking in WT platelets. This might be due to an increased number of integrins 
at the platelet surface after CRP stimulation that allows augmented Aβ40 binding to integrin 
αIIbβ3.  
 
Release of fibrinogen through Aβ-induced GPVI activation and colocalization of 
fibrinogen with Aβ aggregates 
The most abundant of platelet secretory granules are α-granules, which contain about 300 
proteins, including von Willebrand factor (vWF), integrin αIIbβ3 and fibrinogen (26). The 
release of the α-granule content is important for all platelet functions, including hemostasis, 
inflammation and angiogenesis (27). In a previously reported study, we showed that monomeric 
and oligomeric Aβ40 bound to fibrinogen and concluded that fibrinogen bridges Aβ/integrin 
αIIbβ3 complexes of platelets and contributes to the occlusion of cerebral vessels in APP23 mice, 
an Alzheimer’s disease model (19). Thus, we analyzed the release of fibrinogen from platelet 
α-granules upon Aβ40 stimulation. The release of fibrinogen from platelets in response to Aβ40 
was increased and inhibited by losartan comparable to blocking of integrin αIIbβ3 (Fig. 6A). In 
the presence of GPVI-blocking (JAQ1) or αIIbβ3 integrin-blocking (Leo.H4) antibodies, the 
release of fibrinogen was strongly reduced in response to Aβ40 (Fig. 6B). To characterize the 
impact of released fibrinogen on the formation of Aβ aggregates, we incubated murine platelets 
with Aβ40 for 3 days and analyzed fibrinogen and Aβ localization by immunofluorescence 
staining, which revealed that fibrinogen and Aβ aggregates colocalized (Fig. 6C). We also 
observed colocalization of Aβ aggregates and fibrinogen in cultures of human platelets (fig. 
S4A). Blocking of active factor X with the selective inhibitor Arixtra did not alter binding of 
fibrinogen or amyloid fibril aggregate formation suggesting that the conversion of fibrinogen 
to fibrin did not play a role in platelet mediated amyloid fibril aggregate formation (fig. S5).  
The inhibition of GPVI on platelets not only led to reduced aggregation of Aβ but also to less 
accumulation of fibrinogen in cell culture (Fig. 6C, middle panel). Additionally, the inhibition 
of integrin αIIbβ3 by blocking antibodies prevented the formation of Aβ aggregates as well as 
the accumulation of fibrinogen in cell culture (Fig. 6C, lower panel). To confirm the impact of 
GPVI on the release of fibrinogen upon Aβ40 stimulation of platelets, we used platelets from 
WT and GPVI-deficient mice. Western blot analysis revealed that GPVI deficient platelets did 
not release fibrinogen neither upon stimulation with Aβ40 nor in response to the GPVI agonist 
CRP (Fig. 6D).  Reduced formation of Aβ aggregates was accompanied by reduced fibrinogen 
in cell culture using GPVI deficient platelets compared to WT controls (Fig. 6E). Together, 
these results suggested that Aβ40 induced the release of fibrinogen from platelets via GPVI and 
the released fibrinogen co-localized with Aβ aggregates in cell culture.  
 
Reduced Aβ-induced platelet adhesion in vivo by blocking or genetically deleting GPVI  
Platelet adhesion to vascular Aβ plaques in cerebral vessels of transgenic Alzheimer’s disease-
model mice and enhanced Aβ40 triggered platelet adhesion at the injured vessels of wild-type 
mice in vivo were shown in a previous study (18). To explore the inhibitory effects of losartan 
on Aβ40 enhanced platelet adhesion at the vessel in vivo, we analyzed platelet adhesion at the 
injured carotid artery by in vivo fluorescence microscopy. Platelets from donor mice were 
stained with CellTracker™ Red and activated with Aβ40 in the absence or presence of losartan 
(Fig. 7A and Movies S1 and S2). As expected, stimulation of donor platelets with Aβ40-induced 
tethering and stable adhesion of platelets at sites of injury in recipient mice (Fig. 7, A to C). In 
contrast, treatment of donor platelets with Aβ and losartan led to a statistically significant 
reduction of tethered (Fig. 7B) and stable adherent (Fig. 7C) platelets at the injured vessel in 
recipient mice.  
To confirm an important role of GPVI on Aβ40 triggered platelet adhesion at the injured vessel 
in vivo, we used platelets from donor mice lacking GPVI. In vivo fluorescence imaging of 
platelet adhesion at sites of injury in WT recipient mice showed reduced adhesion of Aβ40-




GPVI is one of the key receptors involved in hemostasis and the prothrombotic state of acute 
coronary syndrome, thus targeting GPVI may be therapeutic for thrombosis. Recombinant 
GPVI-Fc improves left ventricular function after experimental myocardial infarction in mice 
(28). Injection of GPVI specific antibodies into mice leads to the depletion of the receptor and 
provides strong protection against arterial thrombosis (29, 30). GPVI is also implicated in 
vascular integrity during development and inflammation (31). Here, our study using platelets 
from patients and mice, revealed that GPVI may also contribute to AD through direct 
interaction with Aβ40 and the consequent release of fibrinogen that amplifies platelet-mediated 
formation of amyloid fibrils. GPVI-blocking antibodies reduced platelet-associated amyloid 
aggregate formation. Aβ40 induced tyrosine phosphorylation in a GPVI-dependent, manner 
including the phosphorylation of LAT. Platelet aggregation, ATP release induced by Aβ40 and 
LAT phosphorylation were reduced in GPVI-deficient murine and human platelets. GPVI 
induced release of fibrinogen accounted for amyloid aggregate formation in vitro. In vivo, 
enhanced platelet accumulation at injured vessels after stimulation of platelets with Aβ40 was 
markedly reduced when we injected GPVI deficient platelets or treated platelets with losartan, 
a small molecule which has been described to inhibit collagen-induced platelet aggregation in 
mice (23, 24), inhibited Aβ40-induced platelet aggregation and ATP and fibrinogen release but 
had no effect on platelet-mediated amyloid aggregate formation. These results are in line with 
studies showing that the use of angiotensin receptor blockers, such as losartan, restore 
cerebrovascular dysfunction but have no effects on memory decline or AD pathology (as in, 
specifically, amyloidosis) (32, 33).  The selective blocking of the angiotensin IV and its 
receptor (AngIV/AT4R)-mediated cascade is suggested to represent the underlying mechanism 
in losartan's benefits. However, our data suggest that the beneficial effect on cerebrovascular 
function is not restricted to the AngIV/AT4R cascade but rather also includes reduction of 
GPVI-induced platelet activation and aggregation, demonstrating broader implications of 
losartan. These results are in line with a study by Elaskalani and colleagues who showed 
reduced platelet aggregation and PLCγ2 phosphorylation in response to Aβ42 when they block 
GPVI by losartan (34).  
Besides collagen, several GPVI ligands have been identified; these include diesel exhaust 
particles (DEP) and large polysaccharides, such as fucoidan and dextran sulfate (35), as well as 
fibrin (36). Here we provide evidence for Aβ40 binding to GPVI and acting as a regulator of 
GPVI signaling including tyrosine phosphorylation, ATP and fibrinogen release and platelet 
aggregation. Activation of GPVI was induced by direct binding of Aβ40 to the receptor and 
most likely not as secondary effect of, say, fibrinogen release, conversion of fibrinogen to fibrin, 
and fibrin-mediated GPVI activation. 
To date, there is only one study that has investigated GPVI in AD. Those authors showed that, 
compared to healthy controls, AD patients have decreased plasma levels of soluble GPVI 
(sGPVI) (37). This finding is of notable interest in terms of an antithrombotic strategy, given 
that sGPVI could bind collagen exposed upon vessel injury and thus reduces its binding to 
platelet GPVI. Reduced sGPVI plasma levels imply increased GPVI exposure at the surface of 
AD platelets, suggesting an increased number of Aβ40-sensitive receptors at the platelet surface 
and thus potentially enhanced Aβ40 binding to platelets in AD patients.  
Our data suggest that the binding of Aβ40 to GPVI induces the release of fibrinogen that is then 
incorporated into amyloid aggregates (Fig. 6). The formation of fibrin might not play a role 
since treatment of platelets with factor X inhibitor Arixtra did not alter platelet induced amyloid 
aggregate formation in culture. Studies have shown that fibrinogen only binds to human but not 
mouse GPVI (38, 39). Because we did not observe differences in the integration of fibrinogen 
into Aβ fibrils using either human or mouse platelets we do not believe that fibrinogen binding 
to GPVI plays a role in platelet induced amyloid aggregate formation. Fibrinogen has been 
identified as possible contributor to the pathology of AD, and reducing fibrinogen decreases 
neurovascular damage, blood-brain barrier permeability and neuroinflammation in AD (40). 
Fibrinogen is a cerebrovascular risk factor that is able to bind to Aβ thereby altering fibrin clot 
structure and degradation (41, 42). The interaction of Aβ and fibrinogen induces fibrinogen 
oligomerization (42). Targeting the interaction of Aβ and fibrinogen is a promising new 
therapeutic approach in AD (43). However, the authors had not taken into consideration that 
platelets might play a role by binding to fibrinogen and / or Aβ. Here, we provide evidence for 
platelets playing an important role in Aβ40-induced release of fibrinogen via GPVI and integrin 
αIIbβ3 and for fibrinogen being involved in platelet induced amyloid aggregate formation.  
We propose that engagement of GPVI and integrin αIIbβ3 by Aβ40 at the platelet surface induces 
the formation of an Aβ fibril network that included binding of Aβ40 to GPVI and integrin αIIbβ3 
as well as fibrinogen binding to Aβ40 and integrin αIIbβ3 (Fig. 7D). These different binding 
possibilities might induce the formation of a specific type of “clustering” of GPVI and integrin 
αIIbβ3. Therefore, it is feasible that the failure of losartan to prevent platelet-mediated Aβ 
aggregate formation is due to its inability to block GPVI clustering as already shown in the 
presence of collagen (24). However, because we previously did not observe integrin activation 
in the presence of Aβ40 alone (19), binding of Aβ40 to GPVI and integrin αIIbβ3 probably did 
not induce integrin inside-out signaling. According to our data, both previously published (19) 
and extended here, Aβ40 binds to non-activated integrin αIIbβ3 on the surface of platelets, and 
this binding is enhanced in the presence of ADP and CRP, probably because of activation-
induced up-regulation of αIIbβ3 at the platelet surface.   
Together, our findings reveal that GPVI mediates platelet-induced amyloid aggregate formation 
through the release of ATP and fibrinogen in response to direct binding of Aβ40 at the platelet 
surface. Further analysis is needed to validate whether blocking GPVI is beneficial to reduce 
amyloid plaque formation in cerebral vessels (as in CAA) and in brain parenchyma.  
 
 
MATERIALS AND METHODS 
Chemicals and antibodies  
Platelets were activated with CRP (Richard Farndale, University of Cambridge, United 
Kingdom) or soluble Aβ40 (1-40; Bachem Peptide, cat no 4014442.1000) sequence single-letter 
code (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV). Aβ1-40 stock 
solutions with a concentration of 1 mg/ml, were solved in sterile H2O and stored at -20 ◦C. 
Apyrase (grade II, from potato) and prostacyclin from Calbiochem were used for isolation. 
Antibodies against phosphotyrosine (Millipore clone 4G10; cat no 05-321), phospho-LAT 
(Tyr200; Abcam cat no ab68139); Aβ1-16 (Biolegend, 6E10, cat no SIG-39320) and fibrinogen 
(Dako cat no A0080) were used for immunoblotting. The antibodies to LAT (cat no 9166), β-
actin (cat no 4967), α-tubulin (cat no 2144), and horseradish peroxidase (HRP)-linked 
secondary antibodies (cat no 7074 and cat no 7076) were from Cell Signaling Technology. 
Animals 
Mice with targeted deletion of GPVI were provided by Jerry Ware and backcrossed to C57BL/6 
mice. For the generation of homozygous WT and Gp6−/−mice, heterozygous breeding partners 
were mated. The animals were maintained in an environmentally controlled room at 22 ± 1 °C 
with a 12 h day-night cycle. Two to five mice were housed in Macrolon cages type III with ad 
libitum access to food (standard chow diet) and water. All animal experiments were conducted 
according the Declaration of Helsinki and approved by the Ethics Committee of the State 
Ministry of Agriculture, Nutrition and Forestry State of North Rhine-Westphalia, Germany 
(reference number: AZ 84-02.05.40.16.073; AZ 81-02.4.2019.A232).  
Human platelet preparation  
Platelets were prepared as previously described (19). Fresh ACD-anticoagulated blood was 
obtained from healthy volunteers (age of 18-50 years, from the blood bank, not AD or GPVI-
deficient) and GPVI-deficient patients as indicated. Participants provided their written informed 
consent to participate in this study according to the Ethics Committee and the Declaration of 
Helsinki (study number 2018-140-KFogU). Collected blood was centrifuged at 200 x g for 
10 min at room temperature. The supernatant (platelet-rich plasma; PRP) was added to 
phosphate buffered saline (PBS; pH 6.5, apyrase: 2.5 U/ml and 1 μM PGI2 in 1:1 volumetric 
ratio and centrifuged at 1000 x g for 6 min. Platelets were resuspended in Tyrode´s-buffer 
solution (140 mM NaCl; 2.8 mM KCl; 12 mM NaHCO3; 0.5 mM Na2HPO4; 5.5 mM glucose 
pH 7.4).  
 
Murine platelet preparation 
Murine blood was acquired by retro bulbar puncture and centrifuged  at 250 x g for 5 min. The 
samples were centrifuged at 50 x g for 6 min to obtain PRP. PRP was washed two times (650 x g 
for 5 min at room temperutre), before the pellet was resuspended in Tyrode’s buffer 
[136 mM NaCl, 0.4 mM Na2HPO4, 2.7 mM KCl, 12 mM NaHCO3, 0.1% glucose, 0.35% 
bovine serum albumin (pH 7.4)] supplemented with prostacyclin (0.5 μM) and apyrase 
(0.02 U/ml). Before use, platelets were resuspended in the same Tyrode´s buffer supplemented 
with 1 mM CaCl2. 
Human and murine cell culture 
Isolated human or murine platelets were preincubated for 15 min with 6 μg per 2*106 platelets 
anti-mouse integrin αIIbβ3 antibody (Leo.H4/Rat IgG2b, emfret ANALYTICS, cat no M021-0] 
or 6 μg per 2*106 platelets anti-mouse GPVI antibody (JAQ1 Rat IgG2a, emfret ANALYTICS, 
cat no M011-0) or 100 µM losartan (Tocris, cat no 3798). The final concentration of 2 × 106 
platelets/well were added to 150 μl of DMEM medium (Dulbecco’s modified Eagle’s medium). 
Platelets were stimulated with 5 μM Aβ40 or 5 µg/ml CRP for 3 days at 37 °C and 5% CO2. 
After three days of incubation unbound platelets were removed by rinsing with PBS. Adherent 
platelets were fixed with 2 % paraformaldehyde and stained against fibrillary Aβ aggregates 
with Congo red according to the manufacturer’s protocol (Millipore cat no 101641). For 
Immunofluorescence staining, slides were washed with 100 μl PBS before fixed with 
2% paraformaldehyde and blocked for 1 h with 5 % goat-serum in PBS. Afterwards slides were 
incubated overnight at 4°C with the primary antibodies against Aβ (mouse-anti-human; 6E10), 
fibrin-[ogen] (rabbit-anti-mouse; DAKO) and the IgG controls in a 1:100 dilution containing 
1% BSA and 5% goat serum in PBS. The next day the chamber slide was washed three times 
with PBS and afterward incubated for 1 h at room temperature with the secondary antibodies 
Alexa Fluor 488- and 555-labelled (Lifetechnologies cat no A32727 and cat no A 32790) in a 
1:250 dilution containing 1% BSA and 5% goat serum in PBS.  
For immunoblotting analysis, the cell culture supernatants were removed and centrifuged at 
10.000 x g for 10 min at 4°C. The supernatant was collected, prepared with reducing sample 
buffer (Laemmli buffer) and denatured at 95 °C for 5 min. 
Cell lysis and immunoblotting     
Platelets (60 × 106) were stimulated with 20 μM soluble Aβ40, or 5 µg/ml CRP in Tyrode’s 
buffer (pH 7.4) at 37 °C for the indicated time. Pretreatment, when indicated, with anti-mouse 
integrin αIIbβ3 antibody (Leo.H4; emfret ANALYTICS), anti-mouse GPVI antibody (JAQ1; 
emfret ANALYTICS), Abciximab (Janssen-Cilag GmbH) or losartan (Cayman chemical 
company) occurred at 37 °C for 15-30 min. For separation into supernatant and pellet, platelets 
were centrifuged at 650 x g. For platelets lysis human platelets were incubated for 15 min on 
ice with lysis buffer containing: 145 mM NaCl, 20 mM tris-HCl, 5 mM EDTA, 0.5 % sodium 
deoxycholat, 1% Triton X-100, and complete protease inhibitor (PI) cocktail (Roche cat no 
5892970001). Murine platelets were incubated for 15 min on ice with lysis buffer containing 
15 mM tris-HCl, 155 mM NaCl, 1 mM EDTA (pH 8.05), 0.005% NaN3, 1% IGPAL and PI. 
Platelet lysates (30 µl) and supernatants (30 µl) were subjected to SDS–polyacrylamide gel 
under reducing conditions and transferred onto nitrocellulose blotting membrane 
(GE Healthcare Life Sciences). Membrane was blocked using 5 % BSA or 5 % non-fat dry milk 
in TBST (Tris-buffered saline with 0.1 % Tween 20) and probed with the appropriate primary 
antibody (dilution 1:1000 in 5% BSA in TBST) and secondary (dilution 1:2500 in 5% non-fat 
dry milk in TBST) HRP-conjugated antibody. Band intensities were quantified in relation to 
untreated platelets using the FUSION-FX7 software (Vilber). 
p-LAT: Under non-aggregating conditions (Apyrase 0.5U/ml, Lotrafiban 10µM and 
indomethacin 10µM), human and mouse platelets (1.5 × 106) were stimulated with 30 μM 
soluble Aβ40, 5 µg/ml CRP or 1 µg/ml Collagen in Tyrode’s buffer (pH 7.4) for the indicated 
time at 37 °C. Cells were immediately lysed on ice with NP-40 lysis buffer (300 mM NaCl, 
20mM Tris, 2mM EGTA, 2mM EDTA and 2% NP-40 detergent) in addition to the protease 
and phosphatase inhibitors (5mM Sodium Orthovanadate, 1mM AEBSF, 10µg/ml leupeptin, 
10µg/ml aprotinin and 1µg/ml pepstatin). Platelet lysates were loaded in a gradient gel 
(NuPAGE 4-12%, Invitrogen) under reducing conditions and transferred onto PVDF blotting 
membrane (TransBlot Turbo, Bio-Rad). Membrane was blocked using 5 % BSA in TBST (TBS 
with 0.1 % Tween 20) and probed with the appropriate primary antibody pLAT (abcam, dilution 
1:500) or α-tubulin (SIGMA, dilution 1:1000), and secondary HRP-conjugated antibody anti-
mouse IgG (GE Healthcare, dilution 1:5000) or anti-rabbit IgG (GE Healthcare, dilution 
1:5000). Band signals were detected using Odyssey Fc imaging system (LI-COR). 
Immunoprecipitation  
1x109 platelets were stimulated with 20 μM Aβ40 for 30 min at 37°C while shaken. Platelets 
without stimulation with Aβ40 were used as a control (resting). Murine resting and 20 µM 
Aβ40-stimulated platelets were lysed with 5 x lysis buffer (as described in Cell lysis and 
immunoblotting) for 10 min on ice. Afterward, the lysate was centrifuged at 10.000 x g for 
10 min at 4°C to clear the lysate from remaining cell fragments. The cleared lysate was 
transferred to a new reaction tube and incubated with GPVI antibody or corresponding IgG 
control (JAQ1; emfret ANALYTICS; Mouse IgG2b Cell Signaling) for 1 h at 4°C. Samples 
were transferred to a new reaction tube and  incubated with washed G-Sepharose protein 
overnight at 4 °C. Samples were washed three times: first time with immunoprecipitation buffer 
(15 mM Tris-HCl; 155 mM NaCl, 1 mM EDTA and 0,005 % NaN3) containing additionally 
1% IGPAL, second and third time only with immunoprecipitation buffer before adding 
2x Laemmli, containing 5% mercaptoethanol and incubated at 95°C for 5 min. After 
centrifugation at 10.000 x g for 2 min supernatants were removed and analyzed via 
immunoblotting against Aβ (Biolegend, 6E10) and GPVI (R&D Systems cat no AF6758).   
Pull-down  
Recombinant GPVI (R&D Systems cat no 6758-GP-050) was covalently immobilized to Pierce 
NHS-Activated Magnetic Beads according to the manufacturer’s information (Thermo 
Scientific cat no 88802). Protein solution with and without 20 µM Aβ40 was added to the GPVI 
coupled beads and incubated at room temperature on a rotator for 1-2 hours. Beads were 
collected with the magnetic stand and washed for three times with wash buffer (TBS with 0.05% 
Tween 20 Detergent) and afterward washed with ultrapure water. For protein elution beads 
were washed with 100 µl elution buffer (0.1M glycine, pH 2.0) and pH was neutralized by 
adding 10 µl neutralization buffer (1M Tris; pH 9).  Laemmli buffer was added and samples 
were analyzed via immunoblotting under reducing conditions against Aβ (Biolegend, 6E10) 
and GPVI (R&D Systems cat no AF6758).   
AVEXIS screening  
Aβ40 peptides or CD200R bait proteins were incubated in MaxiSorp 96-well microtiter plates 
(Nunc) for 1 h, then blocked with 1% BSA for 30 min. The peptide-coated plate was incubated 
with full length recombinant soluble pentameric (s5) GPVI and s5CD200 for 1 h. Three wash 
steps were performed between each incubation using PBS with 0.1% Tween 20. After addition 
of 125 µg/ml nitrocefin (#N005, Toku-e) was added and incubated for 1 h, absorbance was 
measured at 485 nm on VERSA max microplate reader (Molecular Devices). 
Platelet aggregation and ATP release 
Aggregation was measured as percentage light transmission compared to Tyrode’s buffer 
(as=100%) using Chrono-Log dual channel lumi-aggregometer (model 700) at 37 °C stirring at 
1000 rpm. Human ATP-release was assessed applying a luciferin/luciferase bioluminescent 
assay and calculated using a provided ATP standard protocol (all Chrono-Log). Murine ATP-
release was measured using ATP Bioluminescence Assay Kit HS II (Roche; cat no 
11699709001) according to the manufacturer’s information and normalized to resting. 
Flow Cytometry  
Flow Cytometry was performed as described (18, 44). Analysis of Aβ40 binding to platelets 
surface was carried out using fluorophore labeled antibodies for Aβ (anti- Aβ-FITC; Santa Cruz 
cat no sc-28365). 25 µl of washed blood samples were diluted in Tyrode´s buffer with 1 mM 
CaCl2 and stimulated with indicated agonist (5 µM Aβ40; 5 µg/ml CRP) and antibody at room 
temperature for 15 min. Reaction was stopped using 300 µl PBS. Samples were analyzed on a 
FACSCalibur flow cytometer (BD Biosciences).  
Ligation of the carotid artery model 
Carotid ligation in mice were performed as described elsewhere (18). Platelets from WT and 
Gp6−/− donor mice were stained with CellTracker™ Red CMTPX (Invitrogen) according to the 
manufacturer’s guidelines and incubated with losartan (100µM) or vehicle and Aβ (50µg/ml) 
for 30 min. WT littermates mice were anaesthetized using Ketamine (Zoetis) and Xylacine 
(WDT) and put on a heating pad. The right common carotid artery was prepared and after 
intravenous injection of fluorescently labelled and treated platelets a film of 30 s was taken 
using a DM6FS microscope (Leica Microsystems, Wetzlar, Germany). Afterward the carotid 
artery was ligated vigorously for 5 min, thus inducing vascular injury. The interaction of the 
fluorescent platelets with the injured vessel wall was visualized 20 min after ligation by in vivo 
video microscopy. Tethering and adherent cells were counted as means from 10 different 
pictures throughout the film with the same time span between these pictures, but always in the 
same phase of vessel pulsation.  
Statistical analysis  
Data are provided as arithmetic means ± SEM. Significant differences were calculated using 
the two-way ANOVA with Bonferroni’s multiple comparison post hoc test; one-way ANOVA 
with Dunnett’s post hoc test or students t-test as indicated in the figure legends. Outliers were 




Fig. S1. Time-dependent LAT phosphorylation of human platelets stimulated with Aβ40.  
Fig. S2.  Different concentrations of losartan on platelet cell cultures. 
Fig. S3. Reduced amyloid aggregate formation through GPVI inhibition in a concentration-
dependent manner.  
Fig. S4. Immunofluorescence staining of fibrinogen and Aβ in human and murine platelet cell 
cultures.  
Fig. S5. No alteration of amyloid formation upon inhibition of active factor Xa. 
Movie S1. Video of in vivo WT platelet adhesion at the injured carotid artery. 
Movie S2. Video of in vivo WT platelet adhesion at the injured carotid artery after losartan 
treatment. 
Movie S3. Video of in vivo Gp6-/- platelet adhesion at the injured carotid artery. 
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Figure legends 
Fig. 1.  Aβ40 stimulates tyrosine and LAT phosphorylation in a GPVI- and integrin αIIbβ3 
-dependent manner. (A) Western blotting for tyrosine phosphorylation (antibody 4G10) in 
isolated human platelets at rest or upon stimulation with collagen related peptide (CRP, 5 µg/ml) 





antibody abciximab (0.5 µg per 1 Mio cells) for 15 min at room temperature. β-Actin 
served as loading control; n=5 donors. (B) Western blotting for LAT phosphorylation in human 
platelets treated as described in (A) for 30 or 120 sec. Total LAT served as loading control; n=5 
donors. (C) Western blotting for LAT phosphorylation in platelets isolated from a control donor 
and a GPVI-deficient patient; cells were unperturbed (resting) or stimulated with collagen (1 
µg/ml) or Aβ40 (30 µM). α-Tubulin served as loading control; n=2 GPVI-deficient patients and 
n=2 healthy controls. (D) Western blotting for LAT phosphorylation in isolated Gp6−/− and WT 
platelets stimulated with CRP (5 µg/ml) or Aβ40 (20 µM) for 30 or 120 sec. αTubulin served 
as loading control; n=6-7 mice per group. 
 
Fig. 2. Reduced ATP release of GPVI-deficient platelets in response to Aβ40. (A and B) 
Representative ATP release curves (A) and analysis (B) in human platelets pretreated (gray 
traces) with losartan (100 µM) for 20 min then stimulated with CRP (5 µg/ml) or Aβ40 (20 
µM). Data are mean ± SEM from n=5 donors; two-way ANOVA with Bonferroni’s multiple 
comparison post hoc test: **p ≤0.01; ***p ≤0.001. (C) ATP release in WT and Gp6−/−platelets 





blocking antibody Leo.H4 for 20 min. Data are mean ± SEM from 6 to 7 mice per group; CRP 
stimulated platelets served as controls; two-way ANOVA with Bonferroni´s multiple 
comparison post hoc test: *p< 0.05; **p<0.01.  
 
Fig. 3. Reduced aggregation of GPVI-deficient platelets in response to Aβ40. (A and B) 
Representative aggregation curves (A) and the quantified maximum aggregation of platelets 
treated with CRP (5µg/ml) or Aβ40 (20 µM) in the presence or absence of losartan (100 µM 
pretreatment for 20 min). Data are mean ± SEM from n=3-4 donors; two-way ANOVA with 
Bonferroni’s multiple comparison post hoc test, ***p<0.001. (C and D) As described in (A and 
B) in control-donor and GPVI-deficient patient platelets stimulated with Aβ40 (30 µM). Data 
are mean and range from 2 GPVI deficient patients and 2 healthy controls. (E) As described in 
(A and B) in platelets isolated from WT and Gp6−/−mice and treated with CRP (5 µg/ml) or 
Aβ40 (10 µM). Data are mean ± SEM from n=5 mice per group; two-way ANOVA with 
Bonferroni’s multiple comparison post hoc test: ***p<0.001.  
 
Fig. 4. Inhibition or genetic deletion of GPVI decreases amyloid aggregate formation.  (A) 
Isolated human platelets were incubated with Aβ40 (5 µM) at 37°C for 3 days. Afterward 
amyloid aggregates were stained by congo red. Representative pictures of congo red stained 
amyloid aggregates platelet culture in the presence or absence of losartan (100 µM). Scale bar, 
50 µm, n=5experiments. (B) Samples of murine platelets treated as in (A) were stained with 
congo red to visualize amyloid aggregates in the presence of either GPVI-blocking antibody 
JAQ1 or integrin αIIbβ3-blocking antibody Leo.H4 (each at 6 µg per 2 per 2*106 cells). Scale 
bar, 50 µm, n=5 experiments. (C and D) Corresponding Western blotting and quantification of 
soluble Aβ in supernatants from murine platelets cultured as in (B). Leo.H4-treated platelets 
served as control. Data are mean ± SEM from n=5 experiments; Students t-test, *p ≤ 0.05. (E) 
Congo red staining of amyloid aggregates in cultures of platelets from WT and Gp6−/−mice 
without Aβ40 and with Aβ40 (5 µM) in the presence or absence of Leo.H4 (6 µg per per 2 per 
2*106cells). Scale bar, 50 µm, n=5 miceper group. (F and G) Representative Western blots (F) 
and quantification (G) of soluble Aβ in supernatants from WT and GPVI- /- murine platelet 
cultures of remaining soluble Aβ. Controls lacking Aβ40 (lane 1 in the blot) were not regarded 
in the analysis. Data are mean ± SEM from n=5 mice per group two-way ANOVA with 
Bonferroni’s post hoc test, *p< 0.05.   
 
Fig. 5.  Aβ40 binds to GPVI. (A) Interaction screening using AVEXIS (Avidity-based 
Extracellular Interaction Screen). Biotinylated bait peptides Aβ40 (CD200R-BLH is used as 
control) are arrayed on the surface of a streptavidin coated plate and incubated with pentameric 
prey protein s5-GPVI (s5-CD200 is used as control). Interaction produces a color change to 
red. (B) Corresponding quantification of  the colorimetric change after prey-binding at 485 nm 
as represented in (A). n=5experiments , two-way ANOVA with Bonferroni’s post hoc test, 
***p< 0.001 (C) Pulldown was accomplished using immobilized GPVI magnetic beads and 
incubated without and withAβ40 (20 µM). Uncoated beads served as control. 
Immunoprecipitates were blotted against Aβ (6E10) and GPVI. Input = cell lysate. n=3 
experiments. (D) Isolated platelets were stimulated with Aβ40 (20 µM) and immunoprecipitated 
with GPVI antibody. Immunoprecipitates were analyzed via Western blotting against Aβ and 
GPVI. N = 3. (E) WT and Gp6−/− platelets were preincubated with Aβ40 (5 µM), followed by 
an incubation with anti-Aβ-FITC antibody. When indicated platelets were pretreated with 
integrin αIIbβ3-blocking antibody Leo.H4. Binding of Aβ to platelet surface was measured by 
flow cytometry (n = 9-13 mice per group; mean ± SEM; one-way ANOVA with Dunnett’s post 
hoc test within every group, *p< 0.05, **p< 0.01).  
 
Fig. 6. Fibrinogen release in response to Aβ and colocalization with amyloid aggregates in 
cell culture. (A) Western blotting of fibrinogen release in murine platelets upon stimulation 





antibody Leo.H4 (0.5 µg per 1 Mio cells) or with losartan (100 µM)). β-Actin served as loading 
control; representative images of n=3 experiments. (B) Western blotting of fibrinogen release 
in murine platelets as described in (A) pretreated with GPVI-blocking antibody JAQ1 and with 
integrin αIIbβ3-blocking antibody Leo.H4 (each 0.5 µg per 1 Mio cells). Representative Western 
blot of n=3 experiments. (C) Murine platelets were incubated with Aβ40 (5 µM) at 37°C for 3 





 antibody Leo.H4. Immunostaining against amyloid β aggregates (green) and fibrinogen 
(red) visualizes colocalization. Scale bar, 20 μm. Representative images of n=3 experiments. 
(D) Western blot analysis of fibrinogen release in platelets from WT and Gp6−/− mice upon 





 antibody Leo.H4. Representative images of n=3 mice per group. (E) 
Platelets from WT and Gp6−/−mice were incubated with Aβ40 (5 µM) at 37°C for 3 days in the 




 blocking antibody Leo.H4. Immunofluorescence 
staining of fibrinogen (red) and Aβ (green). Scale bar, 20 µm. Representative images of n=3 
mice per group.      
 
Fig. 7. Blocking or deletion of GPVI reduces Aβ-induced platelet adhesion in vivo. (A) 
Images of stable adherent and tethering Aβ40-activated platelets 20 min after carotid artery 
ligation in vivo. WT platelets were either incubated only with Aβ40 (top row) or were pretreated 
with losartan then incubated with Aβ40 (middle row), and Gp6−/− platelets were incubated with 
only Aβ40. Carotid artery vessel wall is outlined using dotted lines. Arrows indicate adherent 
platelets. N=4-5 mice per group. Scale bar, 100 µm. (B and C) Quantification of tethering (B) 
and stable adherent (C) Aβ40-activated platelets. Data are mean± SEM; n = 4-5 mice per group. 
One-way ANOVA with Dunnett’s post hoc test; *p≤0.05, **p≤0.01. (D) Tentative schematic 
illustration. Direct binding of Aβ40 to the collagen receptor GPVI (“1”) initiates 
phosphorylation of LAT (“2”) leading to secretion of granules and thus to the release of ATP, 
ADP, and fibrinogen (“3”). Activation of GPVI and binding of ADP to the P2Y12 receptor 




 from a closed (inactive) to open (active) form leading to 
enhanced binding of Aβ to integrin αIIbβ3. Released fibrinogen bridges binding of soluble Aβ to 




 to induce the formation of amyloid aggregates at the platelet surface 
(“4”).  
